Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforceKathryn Connelly, Cristina Vazquez‐Mateo, Laurie B. Burke et al.|Nature Reviews Rheumatology|2023Cited by 29
Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraineJames M. Martinez, Sandra Garcês, Nada Hindiyeh et al.|Cephalalgia|2020Cited by 14
Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspectiveElena W.Y. Hsieh, Debra Zack, James Chung et al.|RMD Open|2025Cited by 3
AB0982 DOMAINS FOR INCLUSION IN A NOVEL TREATMENT RESPONSE MEASURE FOR SYSTEMIC LUPUS ERYTHEMATOSUS (TRM-SLE): RESULTS OF A MODIFIED DELPHI STUDYKim A. Connelly, Maria Dall’Era, R. Koelmeyer et al.|Annals of the Rheumatic Diseases|2024Cited by 0